Botulinum toxin type A
Phase 3Completed 1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hemifacial Spasm
Conditions
Hemifacial Spasm
Trial Timeline
Dec 1, 2005 → Jan 1, 2007
NCT ID
NCT00276315About Botulinum toxin type A
Botulinum toxin type A is a phase 3 stage product being developed by Ipsen for Hemifacial Spasm. The current trial status is completed. This product is registered under clinical trial identifier NCT00276315. Target conditions include Hemifacial Spasm.
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03017729 | Pre-clinical | Completed |
| NCT02969356 | Approved | Completed |
| NCT02020980 | Pre-clinical | Completed |
| NCT02106351 | Phase 3 | Completed |
| NCT01753336 | Phase 3 | Completed |
| NCT01753349 | Pre-clinical | Completed |
| NCT01682148 | Phase 3 | Terminated |
| NCT01313312 | Phase 3 | Completed |
| NCT01251380 | Phase 3 | Completed |
| NCT01251367 | Phase 3 | Completed |
| NCT00455637 | Phase 2 | Terminated |
| NCT00288509 | Phase 3 | Completed |
| NCT00276315 | Phase 3 | Completed |
| NCT00246142 | Phase 3 | Completed |
| NCT00134810 | Phase 2 | Completed |
| NCT00149240 | Phase 2 | Completed |
| NCT00246155 | Phase 3 | Completed |
| NCT00447772 | Phase 3 | Completed |
| NCT00247559 | Phase 2 | Completed |
| NCT00210444 | Phase 2 | Completed |